Efficacy and safety of salvage-line nivolumab monotherapy for advanced esophageal squamous cell carcinoma: Comparison of 240 mg versus 480 mg doses

Author:

Murashima Yuko1,Yamamoto Shun1,Hirose Toshiharu1,Kadono Toru1,Ikeda Go1,Ohara Akihiro1,Itoyama Mai1,Yokoyama Kazuki1,Honma Yoshitaka1,Ishiyama Koshiro1,Oguma Jyunya1,Daiko Hiroyuki1,Kato Ken1

Affiliation:

1. National Cancer Center Hospital

Abstract

Abstract

Background Nivolumab monotherapy is the standard second-line treatment for advanced esophageal squamous cell carcinoma (ESCC) after failure of platinum-based chemotherapy without anti-PD-1 antibody. Fixed dosing with 240 mg every 2 weeks was approved initially, followed by fixed dosing with 480 mg every 4 weeks based on pharmacokinetics data. However, information on the comparative efficacy and safety of the two doses remains limited. Methods We compared progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and the incidence of adverse events (AEs) between the two doses in 117 patients who received second-line(n=85) or later-line(n=32) nivolumab monotherapy at our institution between January 2016 and December 2021. Results Patient characteristics in the second-line group were as follows (240 mg vs. 480 mg): performance status (PS) 0/1/2, 34/61/5% vs 54/42/4%; prior FP, 81.3 vs. 42.3%. Those in the later-line group were as follows: PS 0/1/2, 28/60/12% vs. 14/86/0%; prior FP, 60.0 vs. 42.8%. ORR was 11.9 vs. 24.0% in the second-line group (p=0.19) and 0 vs. 14.3% in the later-line group (p=0.22). Median PFS was 1.7 vs. 4.1 months on second-line (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.35-1.01, p=0.056) and 1.4 vs. 1.8 months on later-line (HR 0.58, 95% CI 0.23-1.46, p=0.25); AEs of any grade were observed in 58.3 vs. 69.7%, respectively. Conclusions The efficacy and safety of the two doses of nivolumab monotherapy were comparable in patients with advanced ESCC.

Publisher

Springer Science and Business Media LLC

Reference22 articles.

1. Cancer Information Service. Cancer statistics in Japan. https://ganjoho.jp/reg_stat/statistics/stat/cancer/4_esophagus.html Accessed 30 Jan 2023. Cancer Statics. NATIONAL CANCER INSTITUTE https://seer.cancer.gov/statfacts/html/esoph.html Accessed 15 Feb 2023.

2. Comprehensive registry of esophageal cancer in Japan, 2013;Watanabe M;Esophagus,2021

3. Does cigarette smoking and alcohol drinking have interaction for the risk of esophageal cancer?;Oze I;Cancer Med,2019

4. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis;Yousef F;Am J Epidemiol,2008

5. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma;Lagergren J;N Engl J Med,1999

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3